Bioresorbable Vascular Scaffold Korean Expert Panel Report
Authors
Jung-Min Ahn ; Duk-Woo Park ; Sung Jin Hong ; Young Keun Ahn ; Joo-Yong Hahn ; Won-Jang Kim ; Soon Jun Hong ; Chang-Wook Nam ; Do-Yoon Kang ; Seung-Yul Lee ; Woo Jung Chun ; Jung Ho Heo ; Deok-Kyu Cho ; Jin Won Kim ; Sung-Ho Her ; Sang Wook Kim ; Sang-Yong Yoo ; Myeong-Ki Hong ; Seung-Jea Tahk ; Kee-Sik Kim ; Moo Hyun Kim ; Yangsoo Jang ; Seung-Jung Park
Citation
KOREAN CIRCULATION JOURNAL, Vol.47(6) : 795-810, 2017
Bioresorbable vascular scaffold (BRS) is an innovative device that provides structural support and drug release to prevent early recoil or restenosis, and then degrades into nontoxic compounds to avoid late complications related with metallic drug-eluting stents (DESs). BRS has several putative advantages. However, recent randomized trials and registry studies raised clinical concerns about the safety and efficacy of first generation BRS. In addition, the general guidance for the optimal practice with BRS has not been suggested due to limited long-term clinical data in Korea. To address the safety and efficacy of BRS, we reviewed the clinical evidence of BRS implantation, and suggested the appropriate criteria for patient and lesion selection, scaffold implantation technique, and management.